Lancet Respiratory Medicine

Article	Citations
Ensuring fair distribution of COVID-19 vaccines: is an intellectual waiver the answer?	593
Touch, and the absence of it	516
How could we forget?	502
The Troublemaker	429
Long-term oxygen therapy in COPD: what is the evidence?	407
A new chance to treat rheumatoid arthritis lung fibrosis?	384
Postoperative CPAP after major abdominal surgery	373
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress	361
Opioids bring peace to patients with IPF cough	350
RAS inhibition and COVID-19: more questions than answers?	339
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers	331
Alone, lonely, and missed	323
Natalie Mazur—creating an affordable vaccine for RSV	322
Social and environmental determinants of health inequities in childhood asthma	298
Cystic fibrosis treatment: hope for all?	297
Standards for assessing and reporting adverse events	289
IL-6 blockade for COVID-19: a global scientific call to arms	281
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis	277
Paediatric pneumonia: catalysing research priorities for the next decade	258
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial	257
Risk and accuracy of outpatient-identified hypoxaemia for death among suspected child pneumonia cases in rural Bangladesh: a multifacility prospective cohort study	251
Myopericarditis after COVID-19 vaccination: unexpected but not unprecedented	247
Concerns regarding a suggested long COVID paradigm – Authors' reply	233
Moving from collective to distributed epidemiological cancer research	215
How to survive a pandemic	210

Cystic fibrosis: a call for papers for ECFS 2022	208
A novel validated tool to score symptom burden in exercise-induced laryngeal obstruction: can we simplify patient follow-up and research?	196
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys	195
Do chest x-ray-positive, sputum-negative individuals warrant more attention during tuberculosis screening?	195
Risks of lung transplantation in the SARS-CoV-2 era	194
Eat or heat: fuel poverty and childhood respiratory health	187
Each person is a world in COVID-19	186
Time to move away from an oxygen-centric model of pulmonary infarction?	186
2023 American Thoracic Society International Conference	179
Lifetime lung function trajectories and COPD: when the train derails	172
Addressing the origins and health effects of small lungs – Authors' reply	171
Optimising eligibility criteria for lung cancer screening	169
Saving our planet one puff at a time	160
The lung is not a balloon: the self-sealing property of the lung	152
Baricitinib for patients with severe COVID-19—time to change the standard of care?	149
US FDA delays decision on Juul and other leading e-cigarette brands	149
European Respiratory Society International Congress 2021	146
Respiratory support before venovenous ECMO for COVID-19: what is the price?	145
The heart of the matter: modulating therapeutic effects of adrenomedullin in cardiogenic shock	144
Pirfenidone in rheumatoid arthritis-associated interstitial lung disease – Authors' reply	143
The burden of tuberculosis in Libya	140
European Respiratory Society International Congress 2022	139
The elusive goal of COVID-19 vaccine immunity	134
Rapid maxillary expansion in paediatric obstructive sleep apnoea	133
Emily Stone—from lung cancer screening to tobacco control	131
US FDA plans improved tobacco regulation	130
COVID-19 hospital admissions: Brazil's first and second waves compared	129
Hans: finding acceptance and positivity in mindfulness	128
Advancement of asthma management in the past decade	128
US Senate committee investigates asthma inhaler prices	127
Early exposure to general anaesthesia: considerations for age-related vulnerability and behavioural outcomes	122
FLiRTing with danger as SARS-CoV-2 variants evolve	121
Multiplex bacterial PCR for antibiotic stewardship in pneumonia	120
Chronic obstructive pulmonary disease: 10 years of precision-guided success	119
COVID-19, smoking, and cancer: a dangerous liaison	118
Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples	117
Pulmonary manifestations of chronic HPV infection in patients with recurrent respiratory papillomatosis	116
US EPA strengthens PM2·5 air pollution limits	114
Major gaps in childhood pneumonia research priorities remain	111
Changing how we see COPD	111
Treatment of severe COVID-19: a role for JAK and complement inhibitors?	111
The persistent mismeasure of spirometry in women	110
To boost or not to boost: navigating post-pandemic COVID-19 vaccination	110
Discussions on VT4COVID	108
Knowledge gaps in fibrotic interstitial lung disease in pan-Asian populations: data not missing at random?	107
Anti-CTLA-4 in non-small-cell lung cancer: insights from the NIPPON study	106
Interstitial lung disease: a decade of progress and hope	106
Fatal dyspnoea at the Palace of Versailles	106
Deji Adegunsoye—tackling the mysteries of pulmonary fibrosis	106
Serotonin pathway blockade in pulmonary arterial hypertension	104

Video laryngoscopy is not the nemesis of direct laryngoscopy	104
Air pollution, climate change, and lung health in Europe	104
Broad protection from SARS-CoV-2 variants without antigen matching	103
Addressing the post-acute sequelae of SARS-CoV-2 infection: a multidisciplinary model of care	98
Lockdown as the mother of invention: disruptive technology in a disrupted time	98
Convalescent plasma in outpatients with COVID-19	98
Nebulised interferon beta-1a for patients with COVID-19	98
How IPF has changed our lives	96
European Respiratory Society International Congress 2023	95
Discussions on VT4COVID	95
Integrating morphology and treatable traits into the management of ILD	94
Blood eosinophil-guided therapy for COPD exacerbations	94
Once-per-day tacrolimus to reduce chronic lung transplant rejection	92
Optimising the approach to ILD diagnosis: the balance of procedural complications against diagnostic accuracy	92
A leap forward in assessing host-directed therapies for tuberculosis	89
Undetected COVID-19 cases in Africa	89
Vascular mechanisms and manifestations of COVID-19	89
Lung transplantation for COVID-19-associated ARDS	88
Chronic cough and cough hypersensitivity: from mechanistic insights to novel antitussives	87
Azithromycin for the prevention of chronic lung disease of prematurity: not a silver bullet	87
COVID-19 boosters versus primary series: update to a living review	86
Respiratory diseases advocate living with severe asthma	86
Remdesivir saves lives. Were 3 years needed to learn that?	86
Leveraging the pleural space for anticancer therapies in pleural mesothelioma	85
High-dose rifampicin to treat tuberculosis infection: potential and pitfalls	84
Concerns about PRISm	84
New framework to define the spectrum of tuberculosis	84
Concerns regarding a suggested long COVID paradigm	84
MARS 2 trial: the future of pleurectomy decortication in pleural mesothelioma	84
Fighting for air: racial inequity in respiratory health	82
Moving the pathway goalposts: COPD as an immune-mediated inflammatory disease	82
Geography, generalisability, and susceptibility in clinical trials	81
Respiratory syncytial virus-induced disease in healthy infants: we need to offload this burden	81
Risk of COVID-19 hospital admission among children with asthma	81
Selonsertib in adults with pulmonary arterial hypertension (ARROW): a randomised, double-blind, placebo-controlled, phase 2 trial	79
On the front lines of the sepsis crisis: hurdles faced by sepsis researchers, survivors, and family advocates	79
Time to escalate quality assurance in small-cell lung cancer radiotherapy trials – Authors' reply	77
Advancing precision medicine for acute respiratory distress syndrome	76
Artificial intelligence hold promise in the ICU	75
Australia bans engineered stone to prevent silicosis	75
Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations	75
The past 10 years of cystic fibrosis treatment: the road to cure	75
VV-ECMO in severe COVID-19: multidimensional perspectives on the use of a complex treatment	74
Should we ration extracorporeal membrane oxygenation during the COVID-19 pandemic?	73
How repeated influenza vaccination effects might apply to COVID-19 vaccines	73
Lung recruitment before surfactant administration in extremely preterm neonates with respiratory distress syndrome (IN-REC-SUR-E): a randomised, unblinded, controlled trial	72
Restricted spirometry through the lifespan	72
Face masks: all for one and one for all	71
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial	70
Potential for personalised and biomarker-guided COPD self-treatment approaches	70
Extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (MARS 2): a phase 3 randomised controlled trial	70
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study	70
Inhaled corticosteroids: not just for asthma, but for COVID-19?	69
Licensure laws and other barriers to telemedicine and telehealth: an urgent need for reform	68
Could a good night's sleep improve COVID-19 vaccine efficacy?	68
“Yes! We can end TB,” but remember the sequelae in children	68
Easing the stress of chronic cough	66
WHO ends the COVID-19 public health emergency	66
Pause for thought: navigating the complex scientific domains of fatigue and of mindfulness-based practices in sarcoidosis and beyond	66
The course of action for effective anti-cytokine treatment in COVID-19	65
The 2021 USPSTF lung cancer screening guidelines: a new frontier	65
Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study	64
GOLD report: 2022 update	64
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials	64
Interpreting posterior probabilities in Bayesian analyses of clinical trials	64
Online mindfulness-based cognitive therapy for fatigue in patients with sarcoidosis (TIRED): a randomised controlled trial	62
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study	62
Lifetime non-smoker survives stage IV lung cancer four times	60
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership	59
The global burden of pulmonary arterial hypertension: profound but improving?	59
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis	59
Thoracentesis: an old story and some new sources	59
Empirical antibiotic therapy for sepsis: save the anaerobic microbiota	58
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study	58
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial	57
In-hospital and 6-month outcomes in patients with COVID-19 supported with extracorporeal membrane oxygenation (EuroECMO-COVID): a multicentre, prospective observational study	57
Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study	56
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial	56
Use of point-of-care testing for respiratory viruses in hospital	55
Effect of an electronic nicotine delivery system with 0, 8, or 36 mg/mL liquid nicotine versus a cigarette substitute on tobacco-related toxicant exposure: a four-arm, parallel-group, randomised, cont	55

Understanding clinical and biological heterogeneity to advance precision medicine in paediatric acute respiratory distress syndrome	54
The role of antiviral treatment in the COVID-19 pandemic	54
Long COVID: systemic inflammation and obesity as therapeutic targets	53
3-year outcomes of discharged survivors of COVID-19 following the SARS-CoV-2 omicron (B.1.1.529) wave in 2022 in China: a longitudinal cohort study	53
A2BCD: a concise guide for asthma management	52
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phas	52
It is time to include real-world effectiveness data on medicinal product labels	51
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, ran	51
Adaptive servo-ventilation for sleep-disordered breathing in patients with heart failure with reduced ejection fraction (ADVENT-HF): a multicentre, multinational, parallel-group, open-label, phase 3 r	51
Tuberculosis prevalence: beyond the tip of the iceberg	51
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?	51
The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial	51
Concerns regarding a suggested long COVID paradigm	49
Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation	49
Daily use of lateral flow devices by contacts of confirmed COVID-19 cases to enable exemption from isolation compared with standard self-isolation to reduce onward transmission of SARS-CoV-2 in Englan	49
Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with cardiac arrest: a comparative meta-analysis and trial sequential analysis	49
Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial	48
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled	48
Tuberculosis and nutrition: what gets measured gets managed	47
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK	47
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomise	47
Interleukin-6: obstacles to targeting a complex cytokine in critical illness	47
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials	47
Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment	46
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study	46
New reference atlas for pulmonary fibrosis severity score in systemic sclerosis	45
COVID-19: a heavy toll on health-care workers	45
Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study	45
Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial	45
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study	43
Correction to Lancet Respir Med 2024; 12: 129–40	43
Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement	43
Correction Lancet Respir Med 2022; 10: 937–48	43
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis	43
Outcome predictors and patient progress following delivery in pregnant and postpartum patients with severe COVID-19 pneumonitis in intensive care units in Israel (OB-COVICU): a nationwide cohort study	43
Transitioning to gaseous and liquid fuels: a right step towards clean cooking in low-income and middle-income countries	43
Correction to Lancet Respir Med 2020; 8: 696–708	42
Correction to Lancet Respir Med 2019; 7: 745–56	42
How Glasgow's 1957 tuberculosis screening programme could help countries today	42
Correction to Lancet Respir Med 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3	41
Correction to Lancet Respir Med 2021; published online Feb 10. https://doiorg/10.1016/S2213-2600(20)30510-5	41
Correction to Lancet Respir Med 2022; 10: 761–75	41
Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials	40
Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-	40
Correction to Lancet Respir Med 2024; 12: 183–85	40
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial	39
Treating COVID-19-related breathlessness with novel interventions	39
Rituximab for connective tissue disease-associated interstitial lung disease	39
Correction to Lancet Respir Med 2023; 11: 163–75	39
Correction to Lancet Respir Med 2024; 12: 642–54	39
First-line treatment for advanced NSCLC in older patients and those with poor performance status	39
Savolitinib in NSCLC: progress in the MET exon 14 journey	38
Correction to Lancet Respir Med 2022; 10: 650–60	38
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis	38
Correction to Lancet Respir Med 2022; 10: 679–88	38
Correction to Lancet Respir Med 2022; 10: e36–37	38
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multi	37
Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis	36
Classification of early tuberculosis states to guide research for improved care and prevention: an international Delphi consensus exercise	35
Correction to Lancet Respir Med 2024; 12: 799–809	35
Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials	35
Befotertinib—a viable alternative in EGFR-mutant advanced NSCLC?	35
What does the expanding CFTR modulator programme mean for people with cystic fibrosis?	35
Vaccination in the world's top athletes	33
Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment	33
Are women with asthma at increased risk for severe COVID-19?	33
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis	32
Tuberculosis, conflict, and displacement	32
US CDC plans to relax COVID-19 isolation guidelines	32
Genetic associations and lung function in IPF: unexpected answers, persistent questions	31
Improving rural intensive care infrastructure in the USA	31
Monoclonals for patients hospitalised with COVID-19	31
Community-acquired pneumonia: the best candidates for clarithromycin – Authors' reply	31
Platform trials: the future of medical research?	31
Trouble with promoting lung cancer screening in never-smokers – Authors' reply	31
Authors' reply	30
New guidelines for paediatric intensive care unit patients	30
Foritinib in advanced ROS1-rearranged non-small-cell lung cancer in China: a multicentre, open-label, single-arm, phase 2 study	29
Patient-reported outcomes: missing in asthma remission	29
Alin Gragossian: from emergency medicine resident to heart transplant recipient	29
Could routine race-adjustment of spirometers exacerbate racial disparities in COVID-19 recovery?	28
Sunvozertinib: the next candidate of TKI for NSCLC	28
Alex Mazulov—battling bronchiectasis in wartime Ukraine	28
The long shadow of COVID-19 in Africa	28
Time to move away from an oxygen-centric model of pulmonary infarction? – Authors' reply	28
Prescription for e-cigs in the UK	28
Tobacco Slave: Imperial Practices in the Modern Age	28
Cytokine adsorption and ECMO in patients with COVID-19	27
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy – Authors' reply	27
Rethinking the efficacy of awake prone positioning in COVID-19-related acute hypoxaemic respiratory failure	27
Early-phase clinical trials in a pandemic: learning from the response to COVID-19	27
Asthma care for all: lessons from the Philippines	27
Cytokine adsorption and ECMO in patients with COVID-19	27
Smoking, nicotine, and COVID-19	27
Prone positioning might reduce the need for intubation in people with severe COVID-19 – Authors' reply	27